Form 4: Phio Pharmaceuticals CFO Acquires 8,000 Shares of Common Stock

Robert M. Infarinato, CFO of Phio Pharmaceuticals, reports the acquisition of 8,000 shares of common stock on August 13, 2024.

Summary

• Robert M. Infarinato, the VP and Chief Financial Officer of Phio Pharmaceuticals Corp., filed a Form 4 on August 15, 2024.
• The report details a transaction that occurred on August 13, 2024, where Mr. Infarinato acquired 8,000 shares of Phio Pharmaceuticals common stock with a par value of $0.0001.
• These shares were acquired through a restricted stock unit grant, which will vest in three equal annual installments starting on the first anniversary of the grant date.
• Following the reported transaction, Mr. Infarinato beneficially owns 8,000 shares of common stock, including shares underlying unvested restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's stock transaction. While insider buying can be seen as a positive signal, it's not overwhelmingly positive in this context.

Positives

• The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units will vest in three equal annual installments commencing on the first anniversary of the grant date.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Key Dates

Keywords

Form 4, Phio Pharmaceuticals, Insider Trading, Robert M. Infarinato, CFO, Stock Acquisition, Restricted Stock Units, Beneficial Ownership